NCT06807606View on ClinicalTrials.gov

Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2029

Conditions
Hematologic Malignancies
Interventions
DRUG

Drugs Cyclophosphamide

Given as standard of care treatment through IV infusion

DRUG

Fludarabine

Given as standard of care treatment through IV infusion

DRUG

Thiotepa

Given as standard of care treatment through IV infusion

DRUG

Tacrolimus

Given as standard of care treatment through IV infusion

DRUG

Mycophenolate mofetil

Given as standard of care treatment through IV infusion

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER